Aging-related studies

Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackert1 body size and weight Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Ackert1 DXA Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Berndt4 histopathology Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. inbred   (28) both 87wks 2011
Eumorphia2 DXA Body mass, fat mass, lean mass, bone mineral density and content. inbred   (5) both 12, 24, 52 wks 2008
Eumorphia3 glucose tolerance 0 to 180 min after 20% glucose i.p. 16h fast. inbred   (4) both 12, 24, 52 wks 2008
Evsikova1 body weight Body weight inbred   (14) both 25wks 2009
Evsikova1 intake monitoring Food intake, water intake at 6mo. Light phase, dark phase, total. inbred   (14) both 25wks 2009
Evsikova1 monitoring system Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. inbred   (14) both 25wks 2009
Hillebrands1 histopathology Kidney pathology at 20mo. inbred   (23) both 87wks 2014
ITP1 body weight
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Various interventions vs. controls. UM-HET3 population both various 2004-2024
ITP1 colony observation
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Life span study. Various interventions vs. controls. UM-HET3 population both various 2004-2024
ITP1 DXA
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Body composition. Body mass, fat mass, lean mass, water content. Intervention vs. controls. UM-HET3 population both various 2004-2024
ITP1 glucose tolerance
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Postprandial glucose. Invervention vs. controls. UM-HET3 population both various 2004-2024
ITP1 grip strength
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Interventions vs. controls. UM-HET3 population both various 2004-2024
ITP1 histopathology
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Pathology. Percent lesions in liver degeneration, lung tumor, renal organs. Intervention vs. controls. UM-HET3 population both various 2004-2024
ITP1 rotarod
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Interventions vs. controls. UM-HET3 population both various 2004-2024
ITP1 uterus weight
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate 		Uterus weight, ovariectomy study with and without an intervention. UM-HET3 population both various 2004-2024
JaxKOMP-LAP ABR test Auditory brainstem response. KOMP both 66-81wks 2021
JaxKOMP-LAP acoustic startle test Acoustic startle response, prepulse inhibition. KOMP both 66-81wks 2021
JaxKOMP-LAP complete blood count Hematology parameters. KOMP both 66-81wks 2021
JaxKOMP-LAP DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. KOMP both 66-81wks 2021
JaxKOMP-LAP ECG Heart rate and wave intervals. Conscious. KOMP both 66-81wks 2021
JaxKOMP-LAP glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. KOMP both 66-81wks 2021
JaxKOMP-LAP grip strength 3 trials. KOMP both 66-81wks 2021
JaxKOMP-LAP hole board test Exploratory behavior. KOMP both 66-81wks 2021
JaxKOMP-LAP light-dark box Anxiety, avoidance behavior. 20 min test. KOMP both 66-81wks 2021
JaxKOMP-LAP metabolic panel Clinical blood chemistry (plasma). No fast. KOMP both 66-81wks 2021
JaxKOMP-LAP observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). KOMP both 66-81wks 2021
JaxKOMP-LAP open field test Locomotor, exploratory, and anxiety-related behavior. 20 min test, some at 5 min intervals. KOMP both 66-81wks 2021
JaxKOMP-LAP ophthalmoscopy Eye morphology. KOMP both 66-81wks 2021
JaxKOMP-LAP organ weights Heart weight. Raw and normalized to body weight. KOMP both 66-81wks 2021
JaxKOMP-LAP slit lamp Eye morphology. KOMP both 66-81wks 2021
JaxKOMP-LAP Y-maze Spontaneous alternation and other parameters. 8 min test. KOMP both 66-81wks 2021
Johnson1 ABR test Auditory brainstem response. inbred   (51) both 3-12wks and 15-72wks 2000
Johnson3 ABR test Auditory brainstem response. B6.A consomic w/par   (24) both 23-30wks 2012
Johnson4 ABR test Auditory brainstem response. B6.PWD consomic w/par   (28) both 49-63wks 2012
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. inbred   (30) both 52, 78, 104 wks 2008
Korstanje2 histopathology Kidney pathology. Aging study, 6mo, 12mo, 20mo. inbred   (29) m 52, 78, 104 wks 2013
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Nelson1 body weight
with restricted diet 		Restricted diet vs. ad libitum diet. ILSXISS   (44) both max lifespan 2010
Nelson1 colony observation
with restricted diet 		Life span comparison. Restricted diet vs. ad libitum diet. ILSXISS   (44) both max lifespan 2010
Nelson1 NMR
with restricted diet 		Body mass, fat mass, lean mass. Restricted diet vs. ad libitum diet. ILSXISS   (44) both max lifespan 2010
Neuner1 balance beam Time to cross narrow beam, age 6 and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 behavior observation Sensorimotor composite score, age 6 mo and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 biomarker quantification Temporal cortex amyloid level, age 6 and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 body weight Measured every 2 mo, starting at age 2 mo to 16 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 elevated plus maze Distance traveled and arm entries, age 6 mo and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 fear conditioning test Time spent freezing, age 6 mo and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 grip strength Grip strength across 3 trials, age 6 mo and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 inclined screen test Time to right body, age 6 and 14 mo. F1 AD-BXD   (55) both 7-65wks 2019
Neuner1 Y-maze Spontaneous alternation and other parameters measured every 2 mo, from age 2 to 16 mo. F1 AD-BXD   (55) both 7-65wks 2019
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (30) both 26, 52, 78, 104 wks 2007
Petkova1 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Poon1 histopathology Cell proliferation in the rostral migratory stream. BrdU+ cells. inbred   (9) both 13-78wks 2013
Seburn2 gait analysis Aging study, 6mo, 18mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Seburn2 grip strength Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Sundberg1 study archive Histopathology. Aging study. inbred   (28) both 2008
Xing1 ECG Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. inbred   (29) both 26, 52, 87 wks 2008
Xing2 gait analysis Aging study, 6mo, 12mo, 18mo. inbred   (31) both 26, 52, 78 wks 2010
Yuan1 body weight Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan2 colony observation Life span study. Survival curves. Aging study. inbred   (31) both max lifespan 2007
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. inbred   (32) both 26, 52, 78 wks 2008
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. inbred   (32) both 26, 52, 78 wks 2008
Yuan4 colony observation Observed age at vaginal opening (patency). Aging study. inbred   (33) f 2-9wks 2009